| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2841 |
| Trial ID | NCT05119855 |
| Disease | Coronavirus Infectious Disease | Human Papillomavirus Infectious Disease |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Co-treatment | 9vHPV Vaccine |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase3 |
| Recruitment status | Completed |
| Title | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age |
| Year | 2022 |
| Country | United States |
| Company sponsor | Merck Sharp & Dohme LLC |
| Other ID(s) | V503-076|2021-003591-13 |
| Vector information | |||
|
|||
| Cohort1: 9vHPV Vaccine_Day 1_Month 6 | |||||||
|
|||||||
| Cohort2: 9vHPV Vaccine_Day 2_Month 8 | |||||||
|
|||||||